Literature DB >> 20046465

Hemolytic uremic syndrome: Events of the past decade.

Peter N McLaine1.   

Abstract

This article describes the birth of the Canadian Pediatric Kidney Disease Research Centre (CPKDRC) in 1985 and the activities that have transpired as a result of collaborative research at paediatric centres across Canada. These include the National Retrospective Study of Childhood Hemolytic Uremic Syndrome (HUS), National Prospective Study of Risk Factors for Developing Escherichia coli O157:H7 Infection, and Intervention Studies for the Prevention of HUS. A look to the future describes possible studies to determine potential factors (surrogate markers) to identify children who are at risk for developing HUS following verotoxin-producing E coli gastroenteritis, other intervention studies and a more accurate understanding of permanent renal insufficiency in children who have had HUS.

Entities:  

Keywords:  Escherichia coli O157:H7; Hemolytic uremic syndrome; Intervention studies; Risk factors

Year:  2002        PMID: 20046465      PMCID: PMC2798609          DOI: 10.1093/pch/7.8.533

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  28 in total

1.  Leukocytosis in hemolytic-uremic syndrome.

Authors:  M B Salzman; R B Ettenger; J D Cherry
Journal:  Pediatr Infect Dis J       Date:  1991-06       Impact factor: 2.129

2.  Gabexate mesilate plus intravenous gammaglobulin treatment in children with diarrhoea-associated haemolytic uraemic syndrome.

Authors:  Y Kusunoki; K Nobumoto; M Ohkawa; T Watanabe; I Hamada; H Tochimaru
Journal:  Nephron       Date:  1998       Impact factor: 2.847

3.  Genome sequence of enterohaemorrhagic Escherichia coli O157:H7.

Authors:  N T Perna; G Plunkett; V Burland; B Mau; J D Glasner; D J Rose; G F Mayhew; P S Evans; J Gregor; H A Kirkpatrick; G Pósfai; J Hackett; S Klink; A Boutin; Y Shao; L Miller; E J Grotbeck; N W Davis; A Lim; E T Dimalanta; K D Potamousis; J Apodaca; T S Anantharaman; J Lin; G Yen; D C Schwartz; R A Welch; F R Blattner
Journal:  Nature       Date:  2001-01-25       Impact factor: 49.962

4.  Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

Authors:  D Karpman; A Andreasson; H Thysell; B S Kaplan; C Svanborg
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

5.  Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2.

Authors:  S M Scotland; G A Willshaw; H R Smith; B Rowe
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

6.  Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome.

Authors:  P E Ray; X H Liu; L Xu; T Rakusan
Journal:  Pediatr Nephrol       Date:  1999-09       Impact factor: 3.714

7.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.

Authors:  G D Armstrong; E Fodor; R Vanmaele
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

9.  Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome.

Authors:  F Proulx; J P Turgeon; C Litalien; M M Mariscalco; P Robitaille; E Seidman
Journal:  Pediatr Infect Dis J       Date:  1998-10       Impact factor: 2.129

10.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.